MediciNova Stock Target Price and Analyst Consensus
| MNOV Stock | USD 1.33 0.01 0.75% |
The current analyst and expert consensus on MediciNova is Strong Buy, with only one strong buy opinion. The current projected MediciNova target price consensus is 16.50 with 1 analyst opinions. The most common way MediciNova analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview MediciNova executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on MediciNova. We encourage you to use your own analysis of MediciNova to validate this buy or sell advice. MediciNova buy-or-sell recommendation module provides average expert sentiment on the projected MediciNova target price to derive its highest and lowest estimates based on its projected price volatility. Check out Macroaxis Advice on MediciNova to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more information on how to buy MediciNova Stock please use our How to Invest in MediciNova guide.
Lowest Forecast 15.02 | Highest Forecast 18.32 | Target Price 16.5 |
MediciNova |
It's important to approach MediciNova's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize MediciNova price targets
MediciNova's stock target price is an estimate of its future price, usually made by analysts. Using MediciNova's target price to determine if it is a suitable investment can be done through the following steps:- Look at MediciNova's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if MediciNova's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional MediciNova Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of MediciNova is a key component of MediciNova valuation and have some predictive power on the future returns of a MediciNova.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of MediciNova's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Cash Cows Invested a lot of shares | |
 | Chemicals Invested over 40 shares | |
 | FinTech Invested over 50 shares | |
 | Artificial Intelligence Invested few shares | |
 | Momentum Invested over 70 shares | |
 | Driverless Cars Invested over 200 shares | |
 | Automobiles and Trucks Invested over 200 shares | |
Check out Macroaxis Advice on MediciNova to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more information on how to buy MediciNova Stock please use our How to Invest in MediciNova guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for MediciNova Stock analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
The data published in MediciNova's official financial statements usually reflect MediciNova's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of MediciNova. For example, before you start analyzing numbers published by MediciNova accountants, it's critical to develop an understanding of what MediciNova's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of MediciNova's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MediciNova's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in MediciNova's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MediciNova. Please utilize our Beneish M Score to check the likelihood of MediciNova's management manipulating its earnings.